 <h1>Palifermin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of palifermin include:</b> arthralgia, dysesthesia, edema, hyperesthesia, hypoesthesia, increased serum amylase, paresthesia, pruritus, skin rash, tongue edema, dysgeusia, erythema of skin, mouth discoloration, and tongue discoloration.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to palifermin: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, palifermin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking palifermin:</p><p>
<i>More common</i>
</p><ul>
<li>Fever</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Skin rash (severe)</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of palifermin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bad, unusual, or unpleasant (after) taste</li>
<li>blurred vision</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>change in taste</li>
<li>difficulty with moving</li>
<li>discoloration of the tongue</li>
<li>dizziness</li>
<li>flushing or redness of the skin</li>
<li>headache</li>
<li>increased sensitivity to pain</li>
<li>increased sensitivity to touch</li>
<li>itching skin</li>
<li>muscle pain or stiffness</li>
<li>nervousness</li>
<li>pain</li>
<li>pain in the joints</li>
<li>pounding in the ears</li>
<li>rash (mild)</li>
<li>slow or fast heartbeat</li>
<li>swelling</li>
<li>thickening of the tongue</li>
<li>tingling in the hands and feet</li>
<li>unusually warm skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>redness or swelling of the vagina</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>ulceration of the skin</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to palifermin: intravenous powder for injection</i></p><h3>General</h3><p>The most commonly reported side effects included all grades of elevated serum amylase, rash, treatment-emergent infections, and fever.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Peak amylase and lipase increases occurred during cytotoxic therapy, and usually returned to baseline by the day of hematopoietic stem cell infusion.</p>
<p></p>
<p>Most taste and tongue disorders were reversible and mild to moderate in severity, usually occurred within the first 6 days of treatment, and typically lasted 5 days.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): All grades of elevated serum amylase (up to 62%), grades 3 and 4 elevated serum amylase (up to 38%), all grades of elevated serum lipase (up to 28%), mouth/tongue thickness/discoloration (up to 17%), grades 3 and 4 elevated serum lipase (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Oral fungal infection, oral paresthesia</p>
<p><b>Frequency not reported</b>: taste disorder, tongue disorder</p>
<p><b>Postmarketing reports</b>: mouth edema, tongue bumps, tongue edema, tongue redness<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 62%), pruritus (up to 35%), erythema (up to 32%)</p>
<p><b>Common</b> (1% to 10%): grade 3 skin rashes</p>
<p><b>Postmarketing reports</b>: face edema, hand-foot syndrome, palmar-plantar erythrodysesthesia syndrome, skin hyperpigmentation<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Treatment-emergent infections (up to 50%), sepsis/septic shock (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Herpes virus infection, immunogenicity/antibody positivity<sup>[Ref]</sup></p><p>Approximately 50% of patients reported treatment-emergent infections when this drug was given 3 days prior to and 3 days after treatment with melphalan; 47% of patients given this drug 3 days prior to treatment with melphalan reported infections, and 25% of patients given placebo with melphalan reported infection.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (up to 39%), pain (up to 16%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Taste altered (up to 16%), dysesthesia (up to 12%), hyperesthesia (up to 12%), hypoesthesia (up to 12%), paresthesia (up to 12%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 10%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Edema (up to 28%)</p>
<p><b>Postmarketing reports</b>: Edema on the soles, palmar edema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Postmarketing reports</b>: Vaginal edema, vaginal erythema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Cataracts<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Allergic reactions, anaphylactic reactions<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kepivance (palifermin)." Shire US Inc, Florence, KY. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about palifermin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Palifermin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Kepivance</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Mucositis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to palifermin: intravenous powder for injection</i></p><h3>General</h3><p>The most commonly reported side effects included all grades of elevated serum amylase, rash, treatment-emergent infections, and fever.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Peak amylase and lipase increases occurred during cytotoxic therapy, and usually returned to baseline by the day of hematopoietic stem cell infusion.</p><p></p><p>Most taste and tongue disorders were reversible and mild to moderate in severity, usually occurred within the first 6 days of treatment, and typically lasted 5 days.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): All grades of elevated serum amylase (up to 62%), grades 3 and 4 elevated serum amylase (up to 38%), all grades of elevated serum lipase (up to 28%), mouth/tongue thickness/discoloration (up to 17%), grades 3 and 4 elevated serum lipase (up to 11%)</p><p><b>Common</b> (1% to 10%): Oral fungal infection, oral paresthesia</p><p><b>Frequency not reported</b>: taste disorder, tongue disorder</p><p><b>Postmarketing reports</b>: mouth edema, tongue bumps, tongue edema, tongue redness<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 62%), pruritus (up to 35%), erythema (up to 32%)</p><p><b>Common</b> (1% to 10%): grade 3 skin rashes</p><p><b>Postmarketing reports</b>: face edema, hand-foot syndrome, palmar-plantar erythrodysesthesia syndrome, skin hyperpigmentation<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Treatment-emergent infections (up to 50%), sepsis/septic shock (up to 12%)</p><p><b>Common</b> (1% to 10%): Herpes virus infection, immunogenicity/antibody positivity<sup>[Ref]</sup></p><p>Approximately 50% of patients reported treatment-emergent infections when this drug was given 3 days prior to and 3 days after treatment with melphalan; 47% of patients given this drug 3 days prior to treatment with melphalan reported infections, and 25% of patients given placebo with melphalan reported infection.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (up to 39%), pain (up to 16%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Taste altered (up to 16%), dysesthesia (up to 12%), hyperesthesia (up to 12%), hypoesthesia (up to 12%), paresthesia (up to 12%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 10%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Edema (up to 28%)</p><p><b>Postmarketing reports</b>: Edema on the soles, palmar edema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Postmarketing reports</b>: Vaginal edema, vaginal erythema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Cataracts<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Allergic reactions, anaphylactic reactions<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kepivance (palifermin)." Shire US Inc, Florence, KY. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about palifermin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Palifermin Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Mucositis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>